THE LEUKEMIA & LYMPHOMA SOCIETYINC
THE LEUKEMIA & LYMPHOMA SOCIETYINC
THE LEUKEMIA & LYMPHOMA SOCIETYINC
Balance Sheet
Fiscal Year Start:
Jul 1
Assets in 2024 (Year End)
$602,010,519
Investments
64%
Cash & Equivalents
25%
Receivables (Non-Related)
8%
Property, Plant, & Equipment (net)
2%
Prepaid Expenses
<1%
Other Assets
<1%
Related-Party Receivables
0%
Inventories
0%
Liabilities in 2024 (Year End)
$211,058,338
Grants Payable
74%
Payables & Accruals
17%
Deferred Revenue
7%
Other Liabilities
2%
Tax-Exempt Bond Liabilities
0%
Custodial & Escrow Liabilities
0%
Notes Payable / Debt (Non-Related)
0%
Related-Party Payables
0%
Assets
2023
2024
Change
Cash & Equivalents
$89,089,467
$147,766,660
+66%
Receivables (Non-Related)
$29,923,480
$45,469,673
+52%
Related-Party Receivables
-
-
-
Inventories
-
-
-
Prepaid Expenses
$5,045,849
$5,836,452
+16%
Investments
$493,592,749
$387,909,046
-21%
Property, Plant, & Equipment (net)
$13,251,184
$10,752,233
-19%
Other Assets
$12,989,142
$4,276,455
-67%
Total Assets
$643,891,871
$602,010,519
-7%
Liabilities
2023
2024
Change
Payables & Accruals
$21,647,040
$36,559,192
+69%
Grants Payable
$219,704,797
$155,633,120
-29%
Deferred Revenue
$15,561,185
$14,667,950
-6%
Tax-Exempt Bond Liabilities
-
-
-
Custodial & Escrow Liabilities
-
-
-
Notes Payable / Debt (Non-Related)
-
-
-
Related-Party Payables
-
-
-
Other Liabilities
$14,425,281
$4,198,076
-71%
Total Liabilities
$271,338,303
$211,058,338
-22%
Net assets
2023
2024
Change
Restricted Net Assets
$90,672,114
$139,650,438
+54%
Unrestricted Net Assets
$281,881,454
$251,301,743
-11%
Net assets
2023
2024
Change
Net assets
+$372,553,568
+$390,952,181
+5%
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)